Cipla is recalling in the US market 1,40,625 vials of Levalbuterol Inhalation Solution used for relieving shortness of breath and coughing caused by asthma and chronic obstructive pulmonary disease. The drug major is recalling the drug for ‘failed impurities and degradation specifications’.
The vials were manufactured by Cipla at its Pithampur manufacturing facility, near Indore, for Princeton-based Dr Reddy's Laboratories Inc. The nationwide recall has been initiated by the company on April 24 this year.
The recall of the drugs has been initiated under Class-III which FDA defined as ‘a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences’.
Cipla, which has presence in over 150 countries, sells more than 2,000 products across various therapeutic categories. The company has 34 manufacturing facilities that make active pharmaceutical ingredients (APIs) and formulations.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: